James Richard Appleman, Curtis Scribner, Andrew Sharabi, Christopher Argent. "A phase 1 study of the safety, pharmacokinetics, and pharmacodynamics of intermittent oral PRTX007, an IRF7-biased TLR7 agonist prodrug.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.e14606